OncoMatch/Clinical Trials/NCT07300241
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Is NCT07300241 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies NEO-811 for clear cell renal cell carcinoma.
Treatment: NEO-811 — The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapies
Subjects must have progressed on or refused standard therapies
Lab requirements
Blood counts
Hemoglobin ≥10 g/dL, Absolute neutrophil count ≥1000 cells/µL, Platelet count ≥100,000/µL
Kidney function
Estimated glomerular filtration rate (eGFR) ≥60 mL/min
Liver function
AST and ALT ≤2.5 × ULN, or AST and ALT ≤5 × ULN for subjects with liver metastases; Total bilirubin ≤1.5 × ULN
Adequate hematologic, hepatic, and renal function defined as: Hemoglobin ≥10 g/dL, Absolute neutrophil count ≥1000 cells/µL, Platelet count ≥100,000/µL, AST and ALT ≤2.5 × ULN, or AST and ALT ≤5 × ULN for subjects with liver metastases, Total bilirubin ≤1.5 × ULN, Estimated glomerular filtration rate (eGFR) ≥60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEO-811 Grand Rapids Site · Grand Rapids, Michigan
- NEO-811 Long Island Site · Lake Success, New York
- NEO-811-101 NYC Site · New York, New York
- NEO-811 South Carolina Site · Myrtle Beach, South Carolina
- NEO-811 Dallas Site · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07300241 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapies.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages